Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with ankylosing spondylitis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Antibodies, Monoclonal; Golimumab

Criteria

Inclusion Criteria:

• Have a diagnosis of definite akylosing spondylitis for at least 3 months

• Have symptoms of active disease at screening and at baseline

• no active infections

Exclusion Criteria:

• Have other inflammatory diseases that might confound the evaluations of benefit from the golimumab therapy

• Have complete ankylosis of the spine

• Have a history of latent or active granulomatous infection

• Have had a serious infection, or have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 2 months prior to first administration of study agent.